In this study, we have demonstrated that Api is an antiproliferative and proapoptotic agent against the A375 human melanoma cell line, leading to an IC50 of 33.02 μM for the tested dose ranges (0.3–60 μM). This evidence concerns the gene SERPINF2 and melanoma.